Compare ArcelorMittal SA (MT) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ArcelorMittal SA vs Revvity Inc — how do they compare? ArcelorMittal SA trades at $63.54 (market cap $47.06B), while Revvity Inc trades at $152.05 (market cap $17.14B). The key difference: ArcelorMittal SA is far larger — about 2.7× Revvity Inc's market cap, and ArcelorMittal SA pays the higher dividend (0.96%). Which is the better fit depends on your goals — on Pluang, investors hold ArcelorMittal SA for 36 Days and Revvity Inc for 12 Days on average.
| MT | RVTY | |
|---|---|---|
Market Cap | $47.06B | $17.14B |
Volume | 1,545,197 | 2,226,396 |
Sector | Basic Materials | Health |
52-Week High | $78.74 | $157.36 |
52-Week Low | $36.91 | $82.26 |
Typical Hold Time | 36 Days | 12 Days |
Enterprise Value | $56.63B | $19.46B |
Dividend Yield | 0.96% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $61.30, down 5.97% amid bearish technical signals and recent Ukraine plant impairment concerns. The stock shows mixed fundamentals with attractive valuation metrics (P/S 0.76, P/B 0.86) but declining revenue trends from $79.8B in 2022 to $61.4B in 2025. Recent Q2 2026 earnings missed expectations, though management expects stronger second-half performance supported by European demand recovery and strategic investments.
While analyst consensus remains bullish with a $74.33 price target (52% buy ratings), significant risks include ongoing Ukraine operations disruption, $1B impairment charge, and China demand weakness. The current price near support levels presents potential entry point for value investors, but requires careful monitoring of European recovery execution and geopolitical stability.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28. The stock shows bullish technical momentum with consistent earnings beats in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. Operating cash flow improved to $628 million in 2026 from $583 million in 2025.
RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics pose near-term risks. The company faces margin pressures in China and competitive challenges. With 52% analyst buy ratings and strong institutional interest, the stock offers upside to the $165 high target but requires monitoring of Q3 earnings due November 3.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
